Cugene Inc. is a clinical-stage biotechnology company focused on developing innovative biologics-based therapeutics for cancer and autoimmune diseases. Their technology platform leverages expertise in biology and precision protein engineering to create targeted treatments. For autoimmune diseases, Cugene is advancing CUG252, a precision-engineered, long-acting IL-2 that selectively expands regulatory T cells (Tregs) while minimizing toxicity. This approach aims to restore immune homeostasis and suppress autoreactivity, addressing the underlying mechanisms of various autoimmune and inflammatory conditions.

In the oncology space, Cugene has developed TILKine™ and VitoKine™, bispecific technologies designed to target tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment. These engineered IL-2 therapies promote localized TIL expansion and enhance cytotoxic activity against tumors, particularly when combined with immune checkpoint inhibitors. Cugene's commitment to precision immuno-engineering allows for improved cytokine receptor selectivity and enhanced therapeutic efficacy, with the goal of providing transformative treatments for patients with solid tumors and unmet medical needs in both oncology and autoimmune diseases.

United States

Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines that harness specific immune cells to treat autoimmune disease and cancer.

Cugene

Company Details